Patients’ outcome according to ΔSUVmax reduction after 2 and 4 cycles of chemotherapy and the actual consolidation treatment
| Metabolic response according to ΔSUVmax >66% . | N . | % . | 4-year PFS (95% CI) . | P . | 4-year OS (95% CI) . | P . |
|---|---|---|---|---|---|---|
| All | 153 | 84 | 80* (73-86) | .0005* | 87** (80-92) | .0034** |
| R-chemotherapy | 46 | 30 | 76 (61-86) | .37 | 91 (78-97) | .57 |
| High dose therapy + ASCT | 36 | 23 | 89 (73-96) | 92 (76-97) | ||
| Salvage therapy | 67 | 44 | 80 (69-88) | 83 (68-92) | ||
| Salvage therapy followed by ASCT | 36 | 54 | 92 (76-97) | 91 (51-99) | ||
| Salvaged not followed by ASCT | 31 | 46 | 68 (48-81) | 74 (55-86) | ||
| ΔSUVmax PET0-2 ≤66% | ||||||
| All | 30 | 16 | 56* (37-72) | 69** (49-83) | ||
| R-chemotherapy | 4 | 13 | 100 | .23 | 100 | 42 |
| High dose therapy + ASCT | 3 | 10 | 67 (5.4-94.5) | 50 (1-91) | ||
| Salvage therapy | 23 | 77 | 48 (27-66) | 65 (42-81) | ||
| Salvage therapy followed by ASCT | 6 | 26 | 67 (19-90) | 100 | ||
| Salvaged not followed by ASCT | 17 | 74 | 41 (19-63) | 53 (28-73) | ||
| ΔSUVmax PET0-4 >70% | ||||||
| All | 157 | 87 | 84† (77-89) | <.0001† | 91 (84-95) | <.0001†† |
| R-chemotherapy | 48 | 31 | 79 (65-88) | .62 | 96 (84-99) | .42 |
| High dose therapy + ASCT | 39 | 25 | 87 (71-94) | 89 (75-96) | ||
| Salvage therapy | 70 | 45 | 86 (75-92) | 87 (72-94) | ||
| Salvage therapy followed by ASCT | 38 | 54 | 92 (77-97) | 92 (51-99) | ||
| Salvaged not followed by ASCT | 32 | 46 | 78 (59-89) | 81 (63-91) | ||
| ΔSUVmax PET0-2 >66%/ΔSUVmax PET0-4 >70% | ||||||
| All | 141 | 91 | 85‡ (78-90) | .36‡ | 91‡‡ (83-95) | .37‡‡ |
| R-chemotherapy | 44 | 31 | 79 (64-89) | .5 | 95 (83-99) | .55 |
| High dose therapy + ASCT | 36 | 25 | 89 (73-96) | 92 (76-97) | ||
| Salvage therapy | 61 | 43 | 87 (75-93) | 86 (68-95) | ||
| Salvage therapy followed by ASCT | 35 | 57 | 94 (79-98) | 90 (47-98) | ||
| Salvaged not followed by ASCT | 26 | 43 | 77 (56-89) | 81 (60-91) | ||
| ΔSUVmax PET0-2 ≤66%/ΔSUVmax PET0-4 >70% | ||||||
| All | 14 | 9 | 77‡ (47-93) | 85‡‡ (51-96) | ||
| R-chemotherapy | 2 | 14 | 100 | .73 | 100 | .39 |
| High dose therapy + ASCT | 3 | 21 | 67 (5-94) | 50 (1-91) | ||
| Salvage therapy | 9 | 64 | 78 (36-94) | 89 (43-98) | ||
| Salvage therapy followed by ASCT | 3 | 33 | (5-94) | 100 | ||
| Salvaged not followed by ASCT | 6 | 67 | 83 (27-97) | 83 (27-97) | ||
| ΔSUVmax PET0-4 ≤70% | ||||||
| All | 23 | 13 | 35† (17-54) | 57†† (34-74) | ||
| R-chemotherapy | 4 | 17 | 75 (13-96) | .1 | 75 (13-96) | .38 |
| High dose therapy + ASCT | 0 | 0 | ||||
| Salvage therapy | 19 | 83 | 26 (10-47) | 53 (29-72) | ||
| Salvage therapy followed by ASCT | 4 | 21 | 50 (6-84) | 100 | ||
| Salvaged not followed by ASCT | 15 | 79 | 20 (5-42) | 40 (16-63) |
| Metabolic response according to ΔSUVmax >66% . | N . | % . | 4-year PFS (95% CI) . | P . | 4-year OS (95% CI) . | P . |
|---|---|---|---|---|---|---|
| All | 153 | 84 | 80* (73-86) | .0005* | 87** (80-92) | .0034** |
| R-chemotherapy | 46 | 30 | 76 (61-86) | .37 | 91 (78-97) | .57 |
| High dose therapy + ASCT | 36 | 23 | 89 (73-96) | 92 (76-97) | ||
| Salvage therapy | 67 | 44 | 80 (69-88) | 83 (68-92) | ||
| Salvage therapy followed by ASCT | 36 | 54 | 92 (76-97) | 91 (51-99) | ||
| Salvaged not followed by ASCT | 31 | 46 | 68 (48-81) | 74 (55-86) | ||
| ΔSUVmax PET0-2 ≤66% | ||||||
| All | 30 | 16 | 56* (37-72) | 69** (49-83) | ||
| R-chemotherapy | 4 | 13 | 100 | .23 | 100 | 42 |
| High dose therapy + ASCT | 3 | 10 | 67 (5.4-94.5) | 50 (1-91) | ||
| Salvage therapy | 23 | 77 | 48 (27-66) | 65 (42-81) | ||
| Salvage therapy followed by ASCT | 6 | 26 | 67 (19-90) | 100 | ||
| Salvaged not followed by ASCT | 17 | 74 | 41 (19-63) | 53 (28-73) | ||
| ΔSUVmax PET0-4 >70% | ||||||
| All | 157 | 87 | 84† (77-89) | <.0001† | 91 (84-95) | <.0001†† |
| R-chemotherapy | 48 | 31 | 79 (65-88) | .62 | 96 (84-99) | .42 |
| High dose therapy + ASCT | 39 | 25 | 87 (71-94) | 89 (75-96) | ||
| Salvage therapy | 70 | 45 | 86 (75-92) | 87 (72-94) | ||
| Salvage therapy followed by ASCT | 38 | 54 | 92 (77-97) | 92 (51-99) | ||
| Salvaged not followed by ASCT | 32 | 46 | 78 (59-89) | 81 (63-91) | ||
| ΔSUVmax PET0-2 >66%/ΔSUVmax PET0-4 >70% | ||||||
| All | 141 | 91 | 85‡ (78-90) | .36‡ | 91‡‡ (83-95) | .37‡‡ |
| R-chemotherapy | 44 | 31 | 79 (64-89) | .5 | 95 (83-99) | .55 |
| High dose therapy + ASCT | 36 | 25 | 89 (73-96) | 92 (76-97) | ||
| Salvage therapy | 61 | 43 | 87 (75-93) | 86 (68-95) | ||
| Salvage therapy followed by ASCT | 35 | 57 | 94 (79-98) | 90 (47-98) | ||
| Salvaged not followed by ASCT | 26 | 43 | 77 (56-89) | 81 (60-91) | ||
| ΔSUVmax PET0-2 ≤66%/ΔSUVmax PET0-4 >70% | ||||||
| All | 14 | 9 | 77‡ (47-93) | 85‡‡ (51-96) | ||
| R-chemotherapy | 2 | 14 | 100 | .73 | 100 | .39 |
| High dose therapy + ASCT | 3 | 21 | 67 (5-94) | 50 (1-91) | ||
| Salvage therapy | 9 | 64 | 78 (36-94) | 89 (43-98) | ||
| Salvage therapy followed by ASCT | 3 | 33 | (5-94) | 100 | ||
| Salvaged not followed by ASCT | 6 | 67 | 83 (27-97) | 83 (27-97) | ||
| ΔSUVmax PET0-4 ≤70% | ||||||
| All | 23 | 13 | 35† (17-54) | 57†† (34-74) | ||
| R-chemotherapy | 4 | 17 | 75 (13-96) | .1 | 75 (13-96) | .38 |
| High dose therapy + ASCT | 0 | 0 | ||||
| Salvage therapy | 19 | 83 | 26 (10-47) | 53 (29-72) | ||
| Salvage therapy followed by ASCT | 4 | 21 | 50 (6-84) | 100 | ||
| Salvaged not followed by ASCT | 15 | 79 | 20 (5-42) | 40 (16-63) |
,**indicate comparison of 4-year PFS and 4-year OS between patients with either ΔSUVmax PET0-2 ≤ 66% or >66%, respectively.
,††indicate comparison of 4-year PFS and 4-year OS between patients with either ΔSUVmax PET0-4 ≤70% or >70%, respectively.
,‡‡indicate comparison of 4-year PFS and 4-year OS between patients with either ΔSUVmax PET0-2 ≤66%/ΔSUVmax PET0-4 >70% or ΔSUVmax PET0-2 >66%/ΔSUVmax PET0-4 >70%, respectively.